Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Amgen Inc (NASDAQ:AMGN)

174.80
Delayed Data
As of Sep 23
 -0.82 / -0.47%
Today’s Change
130.09
Today|||52-Week Range
176.85
+7.68%
Year-to-Date
Will Amgen (AMGN) Stock Be Helped By FDA Approval of Humira Biosimilar?
Sep 23 / TheStreet.com - Paid Partner Content
Is This New Market the Biggest Investment Idea of the Decade?
Sep 17 / MotleyFool.com - Paid Partner Content
New Setback for Sanofi's Lantus Increases Need for M&A
Sep 22 / TheStreet.com - Paid Partner Content
Novartis Reports Positive Phase II Data on Migraine Drug
Sep 16 / Zacks.com - Paid Partner Content
Amgen (AMGN) Repatha Meets Endpoints in Phase III Study
Sep 21 / Zacks.com - Paid Partner Content
Stock Market News for September 15, 2016
Sep 15 / Zacks.com - Paid Partner Content
Stock Market News for September 21, 2016
Sep 21 / Zacks.com - Paid Partner Content
Takeda earmarks $15bn for US pharma acquisitions
Sep 13 / FT.com - Paid Partner Content
Amgen (AMGN) Parsabiv Gets Positive CHMP Opinion in EU
Sep 19 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Spectrum Pharmaceuticals, Amgen, AbbVie and Vertex...
Sep 13 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close175.62
Today’s open176.27
Day’s range174.61 - 176.85
Volume2,238,657
Average volume (3 months)2,830,667
Market cap$130.8B
Dividend yield2.29%
Data as of 3:59pm ET, 09/23/2016

Growth & Valuation

Earnings growth (last year)+35.22%
Earnings growth (this year)+9.42%
Earnings growth (next 5 years)+8.30%
Revenue growth (last year)+6.49%
P/E ratio17.9
Price/Sales5.83
Price/Book4.69

Competitors

 Today’s
change
Today’s
% change
GILDGilead Sciences-0.15-0.18%
BIIBBiogen-2.23-0.71%
ILMNIllumina Inc-0.01-0.01%
NBIXNeurocrine Bioscienc...-0.22-0.41%
Data as of 4:14pm ET, 09/23/2016

Financials

Next reporting dateOctober 18, 2016
EPS forecast (this quarter)$2.80
Annual revenue (last year)$21.3B
Annual profit (last year)$6.9B
Net profit margin32.52%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Robert A. Bradway
Executive Vice President-
Operations
Esteban Santos
Corporate headquarters
Thousand Oaks, California

Forecasts

Search for Jobs